BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE.
Wiad Lek. 2023;76(7):1636-1641. doi: 10.36740/WLek202307118.
The aim: To examine risk factors and evaluate the use of D-dimer as a biomarker of disease severity and mortality in patients with COVID-19.
Materials and methods: Data from a large NYU Langone Health system were analyzed to examine the prevalence of elevated D-dimer levels at first detection and the trend. A retrospective cohort study of 2,377 patients (NYU Langone Health) with severe COVID-19. Also we conducted a retrospective study based on the mortality database of 247 patients from COVID-19 at the Chernivtsi Regional Clinical Hospital.
Results: Patients with elevated baseline D-dimer were more likely to have critical illness than patients with normal D-dimer (43.9% vs. 18.5%). The frequency of adverse events increased with increasing D-dimer levels. Individuals with D-dimer >2000 ng/mL had the highest risk of critical illness (66.0%).
Conclusions: Thus, the level of D-dimer can be considered an important prognostic factor in COVID-19, as its level is elevated in the vast majority of patients with COVID-19 and correlates with a severe course and high mortality.
探讨 COVID-19 患者中 D-二聚体作为疾病严重程度和死亡率的生物标志物的风险因素和评估其应用。
材料和方法：分析了来自纽约大学朗格尼健康系统的大量数据，以检查首次检测时升高的 D-二聚体水平的患病率和趋势。对 2377 例严重 COVID-19 患者（纽约大学朗格尼健康）进行回顾性队列研究。此外，我们还根据切尔诺夫策地区临床医院 247 例 COVID-19 患者的死亡率数据库进行了回顾性研究。
结果：与 D-二聚体正常的患者相比，基线 D-二聚体升高的患者更有可能患有危重病（43.9%比 18.5%）。不良事件的发生频率随着 D-二聚体水平的升高而增加。D-二聚体>2000ng/mL 的个体患危重病的风险最高（66.0%）。
因此，D-二聚体水平可被视为 COVID-19 的一个重要预后因素，因为其在绝大多数 COVID-19 患者中升高，与严重病程和高死亡率相关。
